Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
159.59
+1.09 (0.69%)
After Hours: 159.59 0.00 (0.00%)
Jul 26, 5:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 156.60 - 159.73
52 week 89.76 - 276.19
Open 157.83
Vol / Avg. 0.00/527,674.00
Mkt cap 3.93B
P/E     -
Div/yield     -
EPS -12.89
Shares 24.60M
Beta -2.45
Inst. own 79%
Aug 3, 2016
Q2 2016 Intercept Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 19, 2016
Intercept Pharmaceuticals Inc Annual Shareholders Meeting
Jun 8, 2016
Intercept Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference
Jun 7, 2016
Intercept Pharmaceuticals Inc at Jefferies Healthcare Conference
May 31, 2016
Intercept Pharmaceuticals Inc Approval of Ocaliva Corporate Call
May 5, 2016
Q1 2016 Intercept Pharmaceuticals Inc Earnings Call
May 5, 2016
Q1 2016 Intercept Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -28466.07% -8139.07%
Operating margin -28629.21% -8237.10%
EBITD margin - -8176.31%
Return on average assets -81.35% -49.77%
Return on average equity -93.19% -54.36%
Employees 405 -
CDP Score - -

Address

450 W 15th St Ste 505
NEW YORK, NY 10011-7082
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Officers and directors

Paolo Fundaro Independent Chairman of the Board
Age: 42
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Sandip S. Kapadia Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Lisa Bright President, International
Age: 48
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 61
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Business and Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Luca Benatti Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Gino Santini Independent Director
Age: 59
Bio & Compensation  - Reuters
Glenn P. Sblendorio Independent Director
Age: 60
Bio & Compensation  - Reuters